ASX
LCT 0.024   Last updated EOD 16th August 2019
Fact sheet
The following fact sheets provide a summary of our current business and research pipeline.
Register for email updates
Register now to receive our newsletter and updates on LCT’s activities and progress.

Fact sheet

Home

Cell therapy for neurodegenerative diseases

LCT is an Australasian biotechnology company improving the wellbeing of people with serious diseases worldwide by discovering, developing and commercialising regenerative treatments which  include naturally occuring cells to restore function.

 

Our lead product, NTCELL®, is an alginate coated capsule containing clusters of neonatal porcine choroid plexus cells. After transplantation NTCELL functions as a biological factory, producing factors to promote new central nervous system growth and repair disease-induced nerve degeneration.

 

The Phase I/IIa clinical trial of NTCELL for the treatment of Parkinson’s disease, in New Zealand, met the primary endpoint of safety and in the three-year follow-up showed persistent long-term improvement in some patients.


Results from this trial were used to design a larger Phase IIb trial to confirm the most effective dose of NTCELL, define any placebo component of the response and further identify the initial target Parkinson’s disease patient sub group. This trial commenced in March 2016. 

 

At 24 months post implant the 4 people with Parkinson’s disease who received 80 capsules continue to show a benefit as measured by the change in the Unified Parkinson’s Disease Rating Scale (UPDRS Part III in the off state). This was greater than the 2 placebo group in that section of the Trial, but not when compared to all the 6 placebo patients (4 from the other groups) in whom responses were quite varied. 


In addition to Parkinson’s disease, NTCELL has the potential to be used in a number of other central nervous system indications, including Huntington’s, Alzheimer’s and motor neurone diseases including amyotrophic lateral sclerosis (ALS).

 

LCT’s proprietary encapsulation technology, IMMUPEL™, allows cell therapies to be used without the need for co-treatment with drugs that suppress the immune system.

 

LCT is listed on the Australian (ASX: LCT) and US (OTCQX: LVCLY) stock exchanges and is incorporated in Australia, with operations based in New Zealand.

— 26 July 2019

Appendix 4C June Quarter

Living Cell Technologies Limited today released its cash flow report for the quarter ended 30 June 2019. The company ended the quarter with a cash balance of $4,907,957 compared to $5,289,405 in the previous quarter.

Read More Read Less

— 23 July 2019

Parkinson's trial two year analysis

The entire data for the two years of the Phase IIb trial of NTCELL® in Parkinson’s disease, examining the effectiveness of encapsulated pig choroid plexus as a treatment of moderate to late stage Parkinson’s disease, has now been extensively analysed by statisticians and other experts.

Read More Read Less
Load More

— 16 September 2017

Sir Richard Faull on RNZ National

On Saturday Morning on RNZ National, LCT Scientific Advisor Sir Richard Faull and businessman Bernie Crosby talk to Kim Hill about the work of the University of Auckland Centre for Brain Research and finding a cure for Parkinson's disease.

Read More Read Less

— 13 June 2017

Pig brain cells implanted into brains of people with Parkinson’s

Would you have pig cells implanted in your brain? Some people with Parkinson’s disease have, in the hope it will stop their disease progressing. The approach is still in the early stages of testing, but initial results from four people look promising, with all showing some improvement 18 months after surgery. Living Cell Technologies, based in Auckland, New Zealand, has been developing a treatment that uses cells from the choroid plexus in pigs. This brain structure makes a cocktail of growth factors and signalling molecules known to help keep nerve cells healthy.

Read More Read Less
Load More
icon

There are no forthcoming events at present.

Load More
Announcements

— 26 July 2019

Appendix 4C June Quarter

Living Cell Technologies Limited today released its cash flow report for the quarter ended 30 June 2019. The company ended the quarter with a cash balance of $4,907,957 compared to $5,289,405 in the previous quarter.

Read More Read Less

— 23 July 2019

Parkinson's trial two year analysis

The entire data for the two years of the Phase IIb trial of NTCELL® in Parkinson’s disease, examining the effectiveness of encapsulated pig choroid plexus as a treatment of moderate to late stage Parkinson’s disease, has now been extensively analysed by statisticians and other experts.

Read More Read Less
Load More
LCT in the News

— 16 September 2017

Sir Richard Faull on RNZ National

On Saturday Morning on RNZ National, LCT Scientific Advisor Sir Richard Faull and businessman Bernie Crosby talk to Kim Hill about the work of the University of Auckland Centre for Brain Research and finding a cure for Parkinson's disease.

Read More Read Less

— 13 June 2017

Pig brain cells implanted into brains of people with Parkinson’s

Would you have pig cells implanted in your brain? Some people with Parkinson’s disease have, in the hope it will stop their disease progressing. The approach is still in the early stages of testing, but initial results from four people look promising, with all showing some improvement 18 months after surgery. Living Cell Technologies, based in Auckland, New Zealand, has been developing a treatment that uses cells from the choroid plexus in pigs. This brain structure makes a cocktail of growth factors and signalling molecules known to help keep nerve cells healthy.

Read More Read Less
Load More
Events
icon

There are no forthcoming events at present.

Load More
Register for email updates
Register now to receive our newsletter and updates on LCT’s activities and progress.